Asset Details
Do you wish to reserve the book?
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Do you wish to request the book?
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
2020
Overview
Background
During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed therapy and drugs could further improve the oncologic outcomes.
Herein a narrative review is performed regarding the main rationale in combining immunotherapy and target therapies with SBRT looking at the available clinical data in case of oligometastatic NSCLC, Melanoma and Kidney cancer.
Material and method
Narrative Review regarding retrospective and prospective studies published between January 2009 to November 2019 with at least 20 patients analyzed.
Results
Concerning the combination between SBRT and Immunotherapy, the correct sequence of remains uncertain, and seems to be drug-dependent. The optimal patients’ selection is crucial to expect substantial benefits to SBRT/Immunotherapy combination and, among several factors. A potential field of interest is represented by the so-called oligoprogressed disease, in which SBRT could improve the long-term efficacy of the existing target therapy.
Conclusions
A low tumor burden seems to be the most relevant, thus making the oligometastatic disease represent the ideal setting for the use of combination therapies with immunological drugs.
Publisher
Springer Science and Business Media LLC,BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Biomedical and Life Sciences
/ Disease
/ Drugs
/ Humans
/ Imaging
/ immunotherapy; metastases-directed therapy; oligometastasis; target therapy
/ Medical physics. Medical radiology. Nuclear medicine
/ Melanoma
/ Methods
/ Neoplasm Metastasis - drug therapy
/ Neoplasm Metastasis - pathology
/ Neoplasm Metastasis - radiotherapy
/ Neoplasms. Tumors. Oncology. Including cancer and carcinogens
/ Non-small cell lung carcinoma
/ Oncology
/ R895-920
/ Review
